Treatment of eye disorders with sirtuin modulators

• US 20070014833A1
• Filed: 10/28/2005
• Published: 01/18/2007
• Est. Priority Date: 03/30/2005
• Status: Abandoned Application

• Current Assignee: Sirtris Pharmaceuticals, Inc. (GlaxoSmithKline PLC)
• Original Assignee: Sirtris Pharmaceuticals, Inc. (GlaxoSmithKline PLC)
• Inventors: Milburn, Michael, Westphal, Christoph, Dipp, Michelle
• Application Number:
  US11/374,278
• Publication Number:
  US 20070014833A1
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61K 31/353 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Sirtuin modulators, particularly sirtuin activators, are useful in treating vision impairment. In general, the sirtuin modulators inhibit the progression of vision impairment resulting from various eye disorders. The invention also includes pharmaceutically acceptable formulations of sirtuin modulators, particular ophthalmically acceptable formulations.

Claims

1. A method for treating vision impairment by administering to a patient a therapeutic dosage of a sirtuin modulator, or a pharmaceutically acceptable salt, prodrug or a metabolic derivative thereof.

2. The method of claim 1, wherein the vision impairment is caused by damage to the optic nerve or central nervous system.

3. The method of claim 2, wherein the optic nerve or central nervous system damage is caused by high intraocular pressure.

4. The method of claim 2, wherein the optic nerve damage is caused by swelling of the nerve.

5. The method of claim 2, wherein the optic nerve damage is caused by ischemia.

6. The method of claim 1, wherein the vision impairment is caused by retinal damage.

7. The method of claim 6, wherein the retinal damage is caused by disturbances in blood flow to the retina.

8. The method of claim 6, wherein the retinal damage is caused by disrupton of the macula.

9. The method of claim 1, further comprising co-administering a drug that increases intraocular pressure.

10. The method of claim 9, wherein the drug is a steroid.

11. The method of claim 1, further comprising co-administering a drug that decreases intraocular pressure.

12. The method of claim 1, wherein the sirtuin modulator is a sirtuin activator.

13. The method of claim 12, wherein the sirtuin activator is resveratrol, an analog thereof, or a prodrug of resveratrol or the analog.

14. The method of claim 12, wherein the sirtuin activator is nicotinamide riboside, an analog thereof, or a prodrug of nicotinamide riboside or the analog.

15. The method of claim 1, wherein the sirtuin modulator is administered ophthalmically.

16. The method of claim 15, wherein the sirtuin modulator is administered as a liquid, cream or gel.

17. The method of claim 16, wherein the sirtuin modulator is administered topically to the eye.

18. The method of claim 17, wherin the sirtuin modulator is administered by injection into the eye.

19. The method of claim 15, wherein the sirtuin modulator is administered by release from an ocular implant.

20. The method of claim 19, wherein the ocular implant is an implantable lens.

21. A method for treating glaucoma by administering to a patient a therapeutic dosage of a sirtuin modulator, or a pharmaceutically acceptable salt, prodrug or a metabolic derivative thereof.

22. The method of claim 21, further comprising administering an additional drug for treating glaucoma.

23. A method for treating optic neuritis by administering to a patient a therapeutic dosage of a sirtuin modulator, or a pharmaceutically acceptable salt, prodrug or a metabolic derivative thereof.

24. The method of claim 23, further comprising administering an additional drug for treating optic neuritis.

25. A method for treating macular degeneration by administering to a patient a therapeutic dosage of a sirtuin modulator, or a pharmaceutically acceptable salt, prodrug or a metabolic derivative thereof.

26. The method of claim 25, further comprising administering an additional drug for treating macular degeneration.

27. A method of treating anterior ischemic optic neuropathy by administering to a patient a therapeutic dosage of a sirtuin modulator, or a pharmaceutically acceptable salt, prodrug or a metabolic derivative thereof.

28. The method of claim 27, further comprising administering an additional drug for treating anterior ischemic optic neuropathy.

29-65. -65. (canceled)